82.77 0.00 (0.00%)
After hours: 4:53PM EST
|Bid||79.01 x 800|
|Ask||82.82 x 900|
|Day's range||80.93 - 83.12|
|52-week range||71.84 - 96.79|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||40.38|
|Earnings date||27-Apr-2020 - 03-May-2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||91.40|
Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians, by encouraging innovative and novel solutions for the challenges currently facing the GVHD community. Each year, the Incyte Ingenuity Award is expected to fund, up to $100,000, one innovative program, idea or initiative that fosters collaboration within the GVHD community to address a specific unmet need.
Incyte Announces Positive Topline Results from Phase 3 TRuE-AD Program evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis
Incyte (INCY) delivered earnings and revenue surprises of 12.07% and 1.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs
Incyte (Nasdaq:INCY) announced today that it will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. ET in Boston.
Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports fourth-quarter 2019 results.
Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.
Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.
Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2019 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 13, 2020.
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Incyte Announces the Validation by the EMA of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma